Djingarey Mamoudou H, Diomandé Fabien V K, Barry Rodrigue, Kandolo Denis, Shirehwa Florence, Lingani Clement, Novak Ryan T, Tevi-Benissan Carol, Perea William, Preziosi Marie-Pierre, LaForce F Marc
Inter-country Support Team for West Africa, World Health Organization, Ouagadougou, Burkina Faso.
Centers for Disease Control and Prevention, Atlanta, Georgia.
Clin Infect Dis. 2015 Nov 15;61 Suppl 5(Suppl 5):S434-41. doi: 10.1093/cid/civ551.
A group A meningococcal conjugate vaccine (PsA-TT) was developed specifically for the African "meningitis belt" and was prequalified by the World Health Organization (WHO) in June 2010. The vaccine was first used widely in Burkina Faso, Mali, and Niger in December 2010 with great success. The remaining 23 meningitis belt countries wished to use this new vaccine.
With the help of African countries, WHO developed a prioritization scheme and used or adapted existing immunization guidelines to mount PsA-TT vaccination campaigns. Vaccine requirements were harmonized with the Serum Institute of India, Ltd.
Burkina Faso was the first country to fully immunize its 1- to 29-year-old population in December 2010. Over the next 4 years, vaccine coverage was extended to 217 million Africans living in 15 meningitis belt countries.
The new group A meningococcal conjugate vaccine was well received, with country coverage rates ranging from 85% to 95%. The rollout proceeded smoothly because countries at highest risk were immunized first while attention was paid to geographic contiguity to maximize herd protection. Community participation was exemplary.
一种A群脑膜炎球菌结合疫苗（PsA-TT）专为非洲“脑膜炎带”研发，并于2010年6月获得世界卫生组织（WHO）预认证。该疫苗于2010年12月首次在布基纳法索、马里和尼日尔广泛使用并取得巨大成功。其余23个脑膜炎带国家希望使用这种新疫苗。
在非洲国家的帮助下，WHO制定了一个优先排序方案，并使用或调整现有的免疫指南来开展PsA-TT疫苗接种活动。疫苗需求与印度血清研究所进行了协调。
布基纳法索是2010年12月首个为其1至29岁人群实现全面免疫的国家。在接下来的4年里，疫苗覆盖范围扩大到生活在15个脑膜炎带国家的2.17亿非洲人。
新型A群脑膜炎球菌结合疫苗广受好评，各国覆盖率在85%至95%之间。推广过程顺利，因为首先对风险最高的国家进行了免疫，同时注重地理毗邻性以最大限度地实现群体保护。社区参与堪称典范。
Zotero 插件
